290 related articles for article (PubMed ID: 32608111)
21. Cannabichromene, Related Phytocannabinoids, and 5-Fluoro-cannabichromene Have Anticonvulsant Properties in a Mouse Model of Dravet Syndrome.
Anderson LL; Ametovski A; Lin Luo J; Everett-Morgan D; McGregor IS; Banister SD; Arnold JC
ACS Chem Neurosci; 2021 Jan; 12(2):330-339. PubMed ID: 33395525
[TBL] [Abstract][Full Text] [Related]
22. Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders.
Golub V; Reddy DS
Adv Exp Med Biol; 2021; 1264():93-110. PubMed ID: 33332006
[TBL] [Abstract][Full Text] [Related]
23. Effects of marihuana cannabinoids on seizure activity in cobalt-epileptic rats.
Colasanti BK; Lindamood C; Craig CR
Pharmacol Biochem Behav; 1982 Apr; 16(4):573-8. PubMed ID: 6280204
[TBL] [Abstract][Full Text] [Related]
24. The Heat Sensing Trpv1 Receptor Is Not a Viable Anticonvulsant Drug Target in the
Satpute Janve V; Anderson LL; Bahceci D; Hawkins NA; Kearney JA; Arnold JC
Front Pharmacol; 2021; 12():675128. PubMed ID: 34079465
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies.
Reddy DS
Exp Neurol; 2023 Jan; 359():114237. PubMed ID: 36206806
[TBL] [Abstract][Full Text] [Related]
26. Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol.
Vann RE; Gamage TF; Warner JA; Marshall EM; Taylor NL; Martin BR; Wiley JL
Drug Alcohol Depend; 2008 Apr; 94(1-3):191-8. PubMed ID: 18206320
[TBL] [Abstract][Full Text] [Related]
27. Different responses of repetitive behaviours in juvenile and young adult mice to Δ
Gorberg V; McCaffery P; Anavi-Goffer S
Br J Pharmacol; 2021 Feb; 178(3):614-625. PubMed ID: 33125731
[TBL] [Abstract][Full Text] [Related]
28. An assessment of concurrent cannabidiol and Δ⁹-tetrahydrocannabinol administration in place aversion and taste avoidance conditioning.
Hempel BJ; Clasen MM; Nelson KH; Woloshchuk CJ; Riley AL
Exp Clin Psychopharmacol; 2018 Apr; 26(2):205-213. PubMed ID: 29648861
[TBL] [Abstract][Full Text] [Related]
29. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology.
Bhattacharyya S; Morrison PD; Fusar-Poli P; Martin-Santos R; Borgwardt S; Winton-Brown T; Nosarti C; O' Carroll CM; Seal M; Allen P; Mehta MA; Stone JM; Tunstall N; Giampietro V; Kapur S; Murray RM; Zuardi AW; Crippa JA; Atakan Z; McGuire PK
Neuropsychopharmacology; 2010 Feb; 35(3):764-74. PubMed ID: 19924114
[TBL] [Abstract][Full Text] [Related]
30. Functional and structural deficits of the dentate gyrus network coincide with emerging spontaneous seizures in an Scn1a mutant Dravet Syndrome model during development.
Tsai MS; Lee ML; Chang CY; Fan HH; Yu IS; Chen YT; You JY; Chen CY; Chang FC; Hsiao JH; Khorkova O; Liou HH; Yanagawa Y; Lee LJ; Lin SW
Neurobiol Dis; 2015 May; 77():35-48. PubMed ID: 25725421
[TBL] [Abstract][Full Text] [Related]
31. Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study.
Sainz-Cort A; Jimenez-Garrido D; Muñoz-Marron E; Viejo-Sobera R; Heeroma J; Bouso JC
J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):561-570. PubMed ID: 34412109
[TBL] [Abstract][Full Text] [Related]
32. Antiseizure effects of the cannabinoids in the amygdala-kindling model.
Fallah MS; Dlugosz L; Scott BW; Thompson MD; Burnham WM
Epilepsia; 2021 Sep; 62(9):2274-2282. PubMed ID: 34251027
[TBL] [Abstract][Full Text] [Related]
33. Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents.
Fasinu PS; Phillips S; ElSohly MA; Walker LA
Pharmacotherapy; 2016 Jul; 36(7):781-96. PubMed ID: 27285147
[TBL] [Abstract][Full Text] [Related]
34. Effects on variable-interval performance in rats of delta 9-tetrahydrocannabinol and cannabidiol, separately and in combination.
Zuardi AW; Karniol IG
Braz J Med Biol Res; 1983 Jul; 16(2):141-6. PubMed ID: 6317104
[TBL] [Abstract][Full Text] [Related]
35. Interactions between cannabidiol and Δ
Todd SM; Zhou C; Clarke DJ; Chohan TW; Bahceci D; Arnold JC
Eur Neuropsychopharmacol; 2017 Feb; 27(2):132-145. PubMed ID: 28043732
[TBL] [Abstract][Full Text] [Related]
36. How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review.
Freeman AM; Petrilli K; Lees R; Hindocha C; Mokrysz C; Curran HV; Saunders R; Freeman TP
Neurosci Biobehav Rev; 2019 Dec; 107():696-712. PubMed ID: 31580839
[TBL] [Abstract][Full Text] [Related]
37. The endocannabinoid system impacts seizures in a mouse model of Dravet syndrome.
Anderson LL; Doohan PT; Hawkins NA; Bahceci D; Garai S; Thakur GA; Kearney JA; Arnold JC
Neuropharmacology; 2022 Mar; 205():108897. PubMed ID: 34822817
[TBL] [Abstract][Full Text] [Related]
38. Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice.
Myers AM; Siegele PB; Foss JD; Tuma RF; Ward SJ
Br J Pharmacol; 2019 May; 176(10):1552-1567. PubMed ID: 29338068
[TBL] [Abstract][Full Text] [Related]
39. Hyperthermia-Induced Seizures Enhance Brain Concentrations of the Endocannabinoid-Related Linoleoyl Glycerols in a
Bahceci D; Anderson LL; Kevin RC; Doohan PT; Arnold JC
Cannabis Cannabinoid Res; 2023 Jun; 8(3):495-504. PubMed ID: 36269656
[No Abstract] [Full Text] [Related]
40. Cannabis, cannabidiol, and epilepsy--from receptors to clinical response.
Szaflarski JP; Bebin EM
Epilepsy Behav; 2014 Dec; 41():277-82. PubMed ID: 25282526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
